Search PubMed⌕ Search

Biomedical subjects

E K Dzhikidze

Publications and source records attributed to E K Dzhikidze.

At least 19 recordsLinked to original sources
PubMed2006

[Campylobacter in the etiology of acute intestinal infections in primates].

The subjects of the study were 1,249 primates of different species, kept in a nursery in the city of Adler. The subjects varied in age, were either clinically healthy, diseased, or dead (the death had been caused by an acute intestinal disease). Biological, molecular-genetic (PCR), and immunological (coagglutination reaction) methods were used in diagnostics of campilobacter infections. The study found campilobacter in 20.9% of healthy animals on the average; this number varied depending on the species and age. The frequency of campilobacter infection in diseased and dead animals was higher than that in healthy ones (40.1% and 20.9%, respectively.) Two types of Campilobacter were identified: C. jejuni (73.4% of cases), and C. coli (14.2%). Clinical and pathomorphological manifestations of campilobacteriosis in primates and humans are similar. The portion of campilobacteriosis in acute intestinal diseases of primates is 40.1%.

Animals↗
PubMed2006

[Monkeys as subjects for study of immunobiological preparations].

The parameters of colon microbiocenosis were evaluated in healthy animals belonging to 6 species of marmosets; its disorders typical of patients with different forms of acute intestinal infections were revealed. Bifidoflora of young monkeys was characterized. The study demonstrated multiple similarities of the microflora of monkeys and humans, including small children. A preclinical study of dry bifidin, a probiotic, revealed its advantages over the commercial bifidumbacterin. 90 monkeys were used for preclinical evaluation of complex immunoglobulin preparation (CIP) and a combination of CIP with interferon (kipferon in suppositories). The study demonstrated sanifying and microflora-normalizing effects, increase of anti-microbial antibodies and serum interferon after both parenteral and rectal administration. The protective activity of a new variant of the probiotic Acilact in exposure to ionizing radiation and anticancer chemotherapy under experimental conditions

Animals↗
PubMed2005

Study of the prevalence of agents of sexually transmitted diseases in monkeys by the gene diagnosis method.

Carriership of agents of sexually transmitted diseases (Trichomonas, Chlamydia, Mycoplasma, Ureaplasma) is highly prevalent in healthy monkeys living in the Adler Breeding Center. The incidence of these microorganisms is appreciably higher in animals with gestoses and labor abnormalities in comparison with animals with normal genital function. Mixed infection caused by 2-4 agents is much more incident than monoinfection.

Animals↗
PubMed2005

Encephalomyocarditis in monkeys.

This paper presents the results of studies of a spontaneous viral infection in monkeys--encephalomyocarditis caused by encephalomyocarditis virus. The infection first detected in the Sukhumi Breeding Center in 1974 was observed in the Adler Breeding Center since 2001. The characteristics of the virus are described and principles of diagnostic by the results of pathologic studies are presented.

Animals↗
PubMed2004

[Infectious pathology of monkeys: a brief description, potential experimental research, safety for attendants at primate care facilities and laboratories].

Infectious diseases of monkeys, including the bacterial anthroponosous and zoogenous as well as viral infections, are described in the paper. A bulwark of research resulted from authors' independent long-term observations of monkey pathologies at Sukhumi and Adler primatological facilities. Pathologies are elucidated, which are better to be modeled in monkeys; there are also diseases that can be studied only in monkeys. Monkey agents were isolated, which are dangerous to humans attending the animals at primatological facilities and laboratories.

Animals↗
PubMed2002

Experimental Mycoplasma infection in monkeys.

Experimental mycoplasma infection was studied in Papio hamadryas, Macaca mulatta, and Macaca nemestrina infected with Mycoplasma (M. pneumoniae and M. hominis) and Ureaplasma (U. urealyticum).

Animals↗
PubMed2002

Detection of Campylobacter jejuni in healthy monkeys and monkeys with enteric infections by PCR.

Campylobacter were detected by PCR in feces of monkeys of different species (clinically healthy, with diarrhea, and dead from acute enteric infections). High prevalence of these bacteria in monkeys was revealed. The incidence of C. jejuni DNA in monkeys with acute enteric infections was higher than in healthy animals (69.6 and 51.3%, respectively). The highest percentage (92.3) of positive results was observed in Macaca mulatta with enteric diseases and in macaque dead of these diseases. The presence of C. jejuni in monkeys with diarrhea and the absence of pathogenic enterobacteria (Shigella, Salmonella, Yersinia) in feces probably attest to etiological relationship of acute enteric infections with Campylobacter.

Animals↗
PubMed2001

Spontaneous simian mycoplasma infection.

We present our many-year studies of spontaneous Mycoplasma infection in monkeys. Mycoplasma flora of healthy, acclimatized, and sick monkeys of different species is characterized. S ome characteristics (including pathogenic properties) of new Acholeplasma isolated from monkeys are described.

Adipose Tissue↗
PubMed1991

Protective ribosomal preparation from Shigella sonnei as a parenteral candidate vaccine.

A parenteral Shigella ribosomal vaccine (SRV) was investigated in animals for safety, antibody-inducing capacity, and protective activity. Ribosomal preparations from a Shigella sonnei phase I avirulent strain were obtained and shown to possess chemical, sedimentation, and other properties typical of bacterial ribosomes. No endotoxin contamination was revealed by a ketodeoxyoctonate assay, although the presence of some kind of O antigen was evidenced by serological findings and the high activity of SRV in inducing the O-antibody response and immunological memory in animals. SRV was nontoxic in mice, guinea pigs, and monkeys and induced no local reactions when injected subcutaneously in reasonable doses. Significant protection against a local Shigella infection (Sereny test) was seen in guinea pigs injected with SRV (efficiency index, about 60%) and the specificity of the protection was evident from cross-challenge experiments. The protective efficiency of SRV was especially high in rhesus monkeys challenged orally with virulent Shigella cells (89%, as calculated from the summarized data of several experiments in 71 animals). Protection in monkeys was long lasting and could be demonstrated several months after injection of SRV. An inexpensive technique can be used for the production of SRV on a large scale. The high immunogenicity of SRV is discussed in terms of the amplifying effect of the ribosome, which serves as a delivery system for polysaccharide O antigen. Further study of SRV as a candidate vaccine for humans seems justified by the data obtained.

Animals↗
PubMed1991

[The immunological status indices of monkeys inoculated with a meningococcal B vaccine].

The method for the determination of bacterial antibodies to group B meningococci was worked out. The method was used for the determination of antibodies to group B meningococcal vaccine produced in the USSR. The dynamic study of antibodies to protein, polysaccharide and lipopolysaccharide antigens of group B meningococci was made by the method of the enzyme immunoassay (EIA), and the safety of the vaccine was studied by the determination of autoantibodies active against brain tissue antigens. The data thus obtained were indicative of the immunological activity of group B protein-polysaccharide vaccines, manifested by the capacity for stimulating bactericidal antibodies whose level increased 8- to 10-fold after the immunization of monkeys in 2 and 3 injections. Similarity in the dynamics of the formation of bacteriolysins and antibodies to protein antigen, as determined in EIA, was noted. The vaccine was found to stimulate no cytotoxic anticerebral antibodies in the glia migration test, which was indicative of the safety of group B meningococcal vaccine.

Animals↗
PubMed1990

[A comparative study of the immunogenicity of 2 group-B meningococcal vaccines in monkeys].

The comparative study of two group B meningococcal vaccines manufactured in the USSR and in Cuba was made. The vaccine manufactured in the USSR contained the noncovalent compound of group B Neisseria meningitidis polysaccharide and outer membrane protein, and the Cuban vaccine contained group B N. meningitidis outer membrane proteins and group C N. meningitidis polysaccharide. The data obtained in this study indicated that both vaccines possessed immunological potency evaluated according to their capacity to stimulate the formation of bactericidal antibodies, whose level was found to increase eightfold after the immunization of monkeys in two injections. Besides, group B meningococcal vaccines did not induce the suppression of nonspecific protective activity characteristics of the body and did not stimulate the formation of autoantibodies to brain and liver tissues, which was indicative of the safety of these vaccines.

Animals↗
PubMed1990

[The quantitative determination of the DNAse activity in Staphylococcus aureus isolated from monkeys].

A new, cheaper and more sensitive method for the quantitative determination of DNAase produced by S. aureus is described. The method permits the determination of DNAase activity in a wider range of titers. The method is based on the detection of the depolymerizing action of staphylococcal nuclease on DNA dyed with ethidium bromide. In this work 22 S. aureus strains isolated from monkeys and 12 strains isolated from humans have been used. The amount of produced by these strains has been determined. The DNAase results of this determination have shown that among S. aureus strains isolated from monkeys and humans the occurrence of strains with both high and low DNAase activity can be observed.

Animals↗
PubMed1988

Parenteral immunization with Shigella ribosomal vaccine elicits local IgA response and primes for mucosal memory.

The parenteral Shigella ribosomal vaccine (SRV), which previously was shown to protect guinea pigs and monkeys, has been compared with lypopolysaccharide (LPS) for its ability to induce a systemic and a local immune response. Injection of SRV caused a significant rise of the serum O antibodies of different classes and the appearance of IgA O antibodies in tears of guinea pigs and saliva and bile of monkeys. In guinea pigs, the local IgA response to parenteral SRV was much more intensive than that to feeding of high doses of LPS, while in monkeys it was nearly as high as that to challenge with a high dose of live pathogen. These data provide an immunological basis for the protective effect of SRV and are in disagreement with the widely accepted view of the inefficiency of parenteral antigens in stimulating mucosal immunity. The results are interpreted from the viewpoint of the role of ribosomes as a delivery system for the Shigella O antigen which provides high potency of SRV in stimulating local lymphoid tissue and makes it a good vaccine candidate.

Administration, Oral↗
PubMed1988

[Stimulation of the secretory IgA system in monkeys by parenteral immunization with a ribosomal Sonne dysentery vaccine].

The experiment was made on 16 monkeys (rhesus macaques). Only 1 out of 12 monkeys immunized with S. sonnei ribosomal vaccine and all 4 control monkeys fell ill as the result of oral challenge with S. sonnei virulent strain. The immunized monkeys stopped excreting Shigellae earlier than the control monkeys. Antibody to lipopolysaccharide (LPS) in the serum and saliva of the monkeys were studied in the enzyme immunoassay with monospecific antibodies to human IgA, IgG and IgM. A single injection of the ribosomal vaccine in a dose of 600 micrograms was shown to lead to a considerable increase in the levels of IgA, IgG and IgM antibodies to LPS in saliva. In parenteral immunization with the ribosomal vaccine the stimulation of secretory IgA system is similar to that resulting from oral challenge with Shigella virulent strain introduced in a dose of 50 X 10(9) microbial cells. No difference in the response of monkeys to primary and booster immunization was noted.

Animals↗